Skip to Content
Merck
All Photos(1)

Key Documents

SML0741

Sigma-Aldrich

ML324

≥98% (HPLC)

Synonym(s):

N-(3-(Dimethylamino)propyl)-4-(8-hydroxyquinolin-6-yl)benzamide

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C21H23N3O2
CAS Number:
Molecular Weight:
349.43
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to light brown

solubility

DMSO: 10 mg/mL, clear

storage temp.

2-8°C

SMILES string

CN(C)CCCNC(C1=CC=C(C2=CC(O)=C(N=CC=C3)C3=C2)C=C1)=O

InChI

1S/C21H23N3O2/c1-24(2)12-4-11-23-21(26)16-8-6-15(7-9-16)18-13-17-5-3-10-22-20(17)19(25)14-18/h3,5-10,13-14,25H,4,11-12H2,1-2H3,(H,23,26)

InChI key

QDBVSOZTVKXUES-UHFFFAOYSA-N

Biochem/physiol Actions

ML324 is a potent JMJD2 demethylase inhibitor that is highly effective in reducing herpes simplex virus (HSV) IE gene expression. ML324 potently blocks the initiation of viral lytic infection and HSV-1 reactivation in the sensory ganglia of latently infected mice.

Features and Benefits

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

David M Carter et al.
SLAS discovery : advancing life sciences R & D, 22(7), 801-812 (2017-03-28)
Human lysine demethylase (KDM) enzymes (KDM1-7) constitute an emerging class of therapeutic targets, with activities that support growth and development of metastatic disease. By interacting with and co-activating the androgen receptor, the KDM4 subfamily (KDM4A-E) promotes aggressive phenotypes of prostate
Lei Duan et al.
Oncogene, 38(28), 5643-5657 (2019-04-11)
Platinum-based drugs such as cisplatin (CP) are the first-line chemotherapy for non-small-cell lung carcinoma (NSCLC). Unfortunately, NSCLC has a low response rate to CP and acquired resistance always occurs. Histone methylation regulates chromatin structure and is implicated in DNA repair.
Salil Saurav Pathak et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 42(4), 854-863 (2016-10-27)
Major depressive disorder (MDD) is debilitating mental illness and is one of the leading contributors to global burden of disease, but unfortunately newer and better drugs are not forthcoming. The reason is lack of complete understanding of molecular mechanisms underlying
Robert Kleszcz et al.
Cellular oncology (Dordrecht), 42(4), 505-520 (2019-05-16)
Activation of the Wnt pathway contributes to the development of head and neck squamous cell carcinomas (HNSCC) and its inhibition has recently emerged as a promising therapeutic strategy. Here, we aimed at identifying suitable molecular targets for down-regulation of canonical
Wenyu Wang et al.
The Journal of experimental medicine, 215(11), 2833-2849 (2018-09-30)
PTEN deficiency in breast cancer leads to resistance to PI3K-AKT inhibitor treatment despite aberrant activation of this signaling pathway. Here, we report that genetic depletion or small molecule inhibition of KDM4B histone demethylase activates the unfolded protein response (UPR) pathway

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service